THE SIXTH INTERNATIONAL CONFERENCE ON MALIGNANCIES IN AIDS AND OTHER IMMUNODEFICIENCIES: BASIC, EPIDEMIOLOGIC AND CLINICAL RESEARCH
MAIN AUDITORIUM, NATCHER CONFERENCE CENTER, NIH CAMPUS
APRIL 22-24, 2002

PROGRAM

MONDAY, APRIL 22

8:00 AM–6:00 PM  POSTER PRESENTATIONS
Atrium on First Floor Concourse and Conference Room E on Lower Level
(Abstracts 32-89)

8:30 AM  Opening Remarks
Ellen Feigal, M.D., National Cancer Institute

8:45-9:35 AM  PLENARY LECTURES
Moderators: Sandra Melnick, Dr. P.H., National Cancer Institute
Joel Palefsky, M.D., F.R.C.P., University of California, San Francisco

8:45  S1 Avoiding the Kiss of Death: How Chronic Viruses Survive
Judy Lieberman, M.D., Center for Blood Research

9:10  S2 Effect of HAART on Human Papillomavirus (HPV)-associated Neoplasia
Richard Reichman, M.D., University of Rochester

9:35-10:20 AM  ABSTRACT PRESENTATIONS

9:35  1 The Effect of HAART on Detection of Anal HPV and Squamous
Intraepithelial Lesions Among HIV-infected Homosexual Men
Nancy Kiviat, M.D., University of Washington and Harborview Medical Center

9:50  2 Effect of HAART on Prevalence of Anal Intraepithelial Neoplasia 2 and 3
Joel Palefsky, M.D., University of California, San Francisco

10:05  3 Population-based HIV-associated Hodgkin's Disease in the San
Francisco Bay Area
Sally Glaser, Ph.D., Northern California Cancer Center

10:20 AM  Break

10:40  PLENARY LECTURE

S3 Impact of Potent Antiretroviral Therapies on the Natural History of
HIV-1 Infection
Constance Benson, M.D., University of Colorado

11:05 AM-12:30 PM  MINI SYMPOSIUM – HIV+ Cancer Patient Care in Resource Poor Countries
Moderators: Jodi Black, Ph.D., National Cancer Institute
David Scadden, M.D., Harvard Medical School and Massachusetts General Hospital
11:05  S4  Brief Overview of AIDS Malignancies and Patient Care in India  
Kapila Bharucha, M.D., B.J. Medical College India

11:30  S5  Viral Lymphoproliferative Diseases in Brazil  
William Harrington, Jr., M.D., University of Miami

S6  AIDS Related Malignancies in Brazil  
Carlos Brites, M.D., Federal University of Bahia, Brazil

11:55  S7  Considerations for International Collaboration in East Africa: Case Western Reserve University (CWRU) Experience  
Scot Remick, M.D., CWRU

Noon  S8  Brief Overview of AIDS Malignancies and Patient Care in Uganda  
Edward Katongole-Mbidde, M.B., Ch.B., Uganda Cancer Institute, Uganda

12:10  S9  Brief Overview of AIDS Malignancies and Patient Care in Kenya  
Walter Mwanda Otieno, M.B., Ch.B., University of Nairobi College of Health Sciences, Kenya

12:20  Panel Discussion

12:30 PM  Lunch (on your own)

1:30-2:15 PM  ABSTRACT PRESENTATIONS  
Moderator: Michael Marco, Treatment Action Group  
Robert Yarchoan, M.D., National Cancer Institute

1:30  4  HIV-1 Related Kaposi’s Sarcoma (KS) in the HAART Era. Non-nucleoside Reverse Transcriptase Inhibitors Are as Effective at Preventing KS as Protease Inhibitors  
Mark Bower Ph.D., F.R.C.P., Chelsea and Westminster Hospital, United Kingdom

1:45  5  Angiogenesis Inhibitor IM862 is Ineffective Against AIDS-KS in a Randomized, Placebo Controlled Trial  
Ariela Noy, M.D., Memorial Sloan-Kettering Cancer Center

2:00  6  Preliminary Results of Combination Liposomal Doxorubicin and Interleukin-12 Followed by Chronic IL-12 Maintenance Therapy in Advanced AIDS-related KS  
Richard Little, M.D., National Cancer Institute

2:15-4:10 PM  PLENARY LECTURES  
Moderators: Alexandra Levine, M.D., Keck School of Medicine, University of Southern California  
Robert Yarchoan, M.D., National Cancer Institute

2:15  S10  National Institutes of Health: Inter-Institute Pilot Program For AIDS Drug Discovery and Development  
Edward Sausville, M.D., National Cancer Institute

2:40  Break

2:55  S11  Molecularly Targeted Approaches in KS Treatment  
S. Gail Eckhardt, M.D., University of Colorado

3:20  S12  Experimental Immune-based Approaches in the Treatment of Lymphomas  
Michael Caligiuri, M.D., The Ohio State University
3:45 S13 Development of Novel Epstein-Barr Virus (EBV)-targeted Treatments for AIDS-associated Lymphoproliferative Disease
Shannon Kenney, M.D., University of North Carolina at Chapel Hill

4:10-4:55 PM ABSTRACT PRESENTATIONS
Moderators: Alexandra Levine, M.D., Keck School of Medicine, University of Southern California
Michael Marco, Treatment Action Group

4:10 7 Humanized Anti-CD20 Monoclonal Antibody for the Treatment of Lymphoproliferative Disease Developing in Pediatric Solid Organ Transplant Recipients
Barbara Savoldo, M.D., Baylor College of Medicine

4:25 8 Front Line Therapy for AIDS-related Lymphoma With Liposomal Doxorubicin (D-99, Myocet), Cyclophosphamide, Vincristine and Prednisone
Anil Tulpule, M.D., Keck School of Medicine, University of Southern California

4:40 9 Infusional Cyclophosphamide, Doxorubicin and Etoposide in HIV-associated Lymphoma: Long-term Followup in ECOG Trial E1494
Joseph Sparano, M.D., Montefiore Medical Center

4:55-5:25 PM Authors at Posters

4:55-6:00 PM RECEPTION
Atrium on First Floor Concourse

TUESDAY, APRIL 23

8:00 AM–6:00 PM POSTER PRESENTATIONS
Atrium on First Floor Concourse and Conference Room E on Lower Level (Abstracts 32-89)

8:30–10:00 AM PLENARY LECTURES - Virus Replication and Immune Responses to Infection
Moderators: Patrick Moore, M.D., Hillman Cancer Center and University of Pittsburgh
Paul Lambert, M.D., University of Wisconsin Medical School

8:30 S14 HPV Replication in Epithelial Cells
Laimonis ‘Lou’ Laimins, Ph.D., Northwestern University

9:00 S15 EBV Glycoproteins and Their Interaction With Receptors
Lindsey Hutt-Fletcher, Ph.D., University of Missouri-Kansas City

9:30 S16 Kaposi’s Sarcoma Herpesvirus (KSHV) Receptors
Bala Chandran, Ph.D., University of Kansas

10:00 AM Break

10:15 AM-12:15 PM ABSTRACT PRESENTATIONS

10:15 10 The Virion-associated Glycoprotein B of KSHV and Its Macaque Homolog, Retroperitoneal Fibromatosis Herpesvirus Contain a Conserved RGD Domain Which Mediates Binding to a Cellular Integrin Receptor
Timothy Rose, Ph.D., University of Washington
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>11</td>
<td>Identification and Characterization of a Polycistronic Transcript of Rhesus Monkey Rhadinovirus (RRV) Encoding for the RRV Orf 50/Rta Transactivator and the RRV R8 and R8.1 Genes</td>
<td>Blossom Damania, Ph.D.</td>
<td>University of North Carolina-Chapel Hill</td>
</tr>
<tr>
<td>10:45</td>
<td>12</td>
<td>Early Events in KSHV Infection of Primary Endothelial Cells</td>
<td>Bruce J. Dezube, M.D.</td>
<td>Beth Israel Deaconess Medical Center</td>
</tr>
<tr>
<td>11:00</td>
<td>13</td>
<td>Identification of the KSHV Lytic Origin of DNA Replication</td>
<td>Yan Yuan, Ph.D.</td>
<td>University of Pennsylvania</td>
</tr>
<tr>
<td>11:15</td>
<td>14</td>
<td>The KSHV Lytic Replication-associated Protein Causes p21-mediated G1 Cell Cycle Arrest During Viral Lytic Replication Through the Induction of CCAAT/Enhance-binding Protein Alpha</td>
<td>Frederick Wu, A.B.D.</td>
<td>Johns Hopkins School of Medicine</td>
</tr>
<tr>
<td>11:30</td>
<td>15</td>
<td>The Epstein-Barr SM Protein Activates STAT1 and Induces Interferon Stimulated Gene Expression by an Interferon-independent Mechanism</td>
<td>Sankar Swaminathan, M.D.</td>
<td>University of Florida Shands Cancer Center</td>
</tr>
<tr>
<td>11:45</td>
<td>16</td>
<td>Histone Deacetylase Inhibitors Reactivate KSHV</td>
<td>Nickolai Talanin, M.D.</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>Noon</td>
<td>17</td>
<td>KSHV ORF 34 Promoter Encodes a Functional Hypoxia Response Element That Is Induced by HIF-2 Alpha</td>
<td>Muzammel Haque, Ph.D.</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>12:15 PM</td>
<td></td>
<td>Lunch (on your own)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15</td>
<td>S17</td>
<td>Functions of the HPV E6 Protein</td>
<td>Elliot Androphy, M.D.</td>
<td>University of Massachusetts Medical School</td>
</tr>
<tr>
<td>1:45</td>
<td>S18</td>
<td>EBERs and Their Effects in Latent EBV Infection</td>
<td>Jeffrey Sample, Ph.D.</td>
<td>St. Jude Children’s Hospital</td>
</tr>
<tr>
<td>2:15</td>
<td>S19</td>
<td>Expression of KSHV in Human Malignancies</td>
<td>Patrick Moore, M.D.</td>
<td>Columbia University</td>
</tr>
<tr>
<td>2:45</td>
<td></td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td>S20</td>
<td>B Cell Development and Oncogenesis</td>
<td>Ralf Küppers, Ph.D.</td>
<td>University of Cologne, Germany</td>
</tr>
<tr>
<td>3:30</td>
<td>18</td>
<td>KSHV and HIV-1 Infections in a Cohort of Mother/Infant Pairs in Zambia</td>
<td>Charles Wood, M.D.</td>
<td>University of Nebraska-Lincoln</td>
</tr>
<tr>
<td>3:45</td>
<td>19</td>
<td>KSHV Latency Associated Nuclear Antigen (LANA) Immortalizes Primary Human Umbilical Vein Endothelial Cells</td>
<td>Andrew Blauvelt, M.D.</td>
<td>National Cancer Institute</td>
</tr>
</tbody>
</table>
4:00  20  KSHV-induced Upregulation of the C-kit Proto-oncogene as Identified by Gene Expression Profiling Induces Endothelial Cell Transformation  
Klaus Früh, Ph.D., Oregon Health and Science University

4:15  21  The Role of EBV Nuclear Protein 3A in Lymphocyte Transformation  
Seiji Maruo, M.D., Ph.D., Brigham and Women’s Hospital

4:30  22  Activation of the P13-Kinase AKT Pathway by EBV Latent Membrane Protein 2A  
Jennifer Harrelson, B.S., University of North Carolina-Chapel Hill and Lineberger Comprehensive Cancer Center

4:45  23  Constitutively Activated STAT3 Induces Survivin Expression and Prevents Apoptosis in Primary Effusion Lymphoma Cells  
Yoshiyasu Aoki, M.D., Ph.D., National Cancer Institute

5:00-5:30 PM  Authors at Posters

5:00-6:00 PM  RECEPTION  
Atrium on First Floor Concourse

WEDNESDAY, APRIL 24

8:00 – 11:45 AM  POSTER PRESENTATIONS  
Atrium on First Floor Concourse and Conference Room E on Lower Level  
(Abstracts 32-90)

8:30–10:00 AM  PLENARY LECTURES - Virus Latency, Persistence, and Immune Responses  
Moderators: Kenneth Cremer, Ph.D., National Cancer Institute  
Elliott Kieff, M.D., Ph.D., Channing Laboratories, Brigham and Women's Hospital, and Harvard University

8:30   S21  HPV VLP Vaccines and Prevention of HPV 16 Infection and Oncogenesis  
Laura Koutsky, Ph.D., University of Washington

9:00   S22  EBNA-1 and Initiation of Episome DNA Synthesis  
John Yates, Ph.D., Roswell Park Cancer Institute

9:30   S23  A KSHV-encoded Interferon Regulatory Factor Expressed in Latency  
Frank Neipel, M.D., University of Erlangen, Germany

10:00 - Noon  ABSTRACT PRESENTATIONS

10:00   24  Lymphoproliferative Cellular Immune Response to HPV 16 E6 and E7 Peptides in HIV Infected Women Are Independent of CD4 Counts, but Are Associated With Clearance of HPV Infection  
Anna Kadish, M.D., Albert Einstein College of Medicine

10:15   25  Detection of KSHV in the Saliva of Immunocompetent and Immunosuppressed Individuals  
Jennifer Webster-Cyriaque, D.D.S., Ph.D., University of North Carolina at Chapel Hill

10:30   26  Defective OCT Transcription Factor Expression/Activity May Explain Impaired Immunoglobulin Expression in KSHV-Infected Primary Effusion Lymphoma Cells  
Daniel DiBartolo, B.A., Cornell University - Weill Medical College
10:45  28  Telomeric Proteins Regulate Plasmid Maintenance of EBV  
       Paul Lieberman, Ph.D., Wistar Institute

11:00  29  The KSHV LANA Is Targeted to Chromosomes by Two Chromosome  
       Associated Proteins Through Both LANA N- and C-terminal Interactions  
       Anita Krithivas, B.S., Johns Hopkins University School of Medicine

11:15  30  Tumorigenesis After Experimental Infection in an EBV Animal Model  
       Fred Wang, M.D., Harvard Medical School

11:30  31  EBV and Breast Cancer: Association Without Causality?  
       Jian Huang, M.S.E., Johns Hopkins Sidney Kimmel Comprehensive Cancer  
       Center

11:45  End of Conference

**CME**
The National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) designates this educational activity for a maximum of 17.5 hrs in Category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. To obtain certification of attendance, please obtain a CME form from the registration desk outside the main auditorium.